Mobile

Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-N...

Mise à jour : Il y a 4 ans
Référence : EUCTR2013-002780-26

Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

- To evaluate the steady state pharmacokinetics (PK) for elvitegravir and tenofovir alafenamide and confirm the dose of the E/C/F/TAF single tablet regimen (STR) in HIV-1 infected, antiretroviral (ARV) treatment-naive adolescents. - To evaluate the safety and tolerability of the E/C/F/TAF STR through Week 24 in HIV-1 infected, ARV treatment-naive adolescents

Critère d'inclusion

  • Human Immunodeficiency Virus (HIV-1) Infection